In addition to complementing AAV manufacturing, the company’s Plasmid DNA (pDNA) platform is now available as a standalone service.

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

VintaProcess can deliver extended vector production up to 7 days post-transfection, significantly improving the yield and proportion of full capsids over time. Unlike traditional AAV manufacturing ...

Enhanced AAV Critical Quality Attributes (CQAs) Streamline the Transition from AAV Vector Design to Comprehensive Gene Therapy QC Characterization Guangping Gao, PhD, Professor & Chair ...

First, the researchers developed an AAV (AAV-Sia6e) that can deliver genome editing tools to a wide range of inner ear cells that form gap junctions. AAV is a useful vector for delivering genes ...

Takeda ended early-stage AAV work in 2023, and, earlier this year, Pfizer pulled the AAV-using hemophilia B gene therapy Beqvez from shelves. With Beqvez off the market, Pfizer now has no ...

(Nasdaq: AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial ...

Plasmidsaurus, the company that sequences while you sleep, today announced the launch of a new product update that delivers ...

From AI-assisted AAV capsid engineering to immunogenicity assays, from high-productivity vector manufacturing process improvement to robust process analytics tools, PackGene's integrated approach ...

Innovations in high-yield AAV production, in-process analytics, and targeted capsid design aim to make gene ... from high-productivity vector manufacturing process improvement to robust process ...